Search

Your search keyword '"Uemura, Hiroji"' showing total 1,412 results
Start Over Author "Uemura, Hiroji"
1,412 results on '"Uemura, Hiroji"'

55. Clinical management of nonobstructive azoospermia: An update.

Author

Takeshima, Teppei, Karibe, Jurii, Saito, Tomoki, Kuroda, Shinnosuke, Komeya, Mitsuru, Uemura, Hiroji, and Yumura, Yasushi

Subjects
AZOOSPERMIA, MALE infertility, SPERM donation, ARTIFICIAL insemination, ORGAN culture, KALLMANN syndrome, FREEDOM of information
Abstract

Approximately 1% of the general male population has azoospermia, and nonobstructive azoospermia accounts for the majority of cases. The causes vary widely, including chromosomal and genetic abnormalities, varicocele, drug‐induced causes, and gonadotropin deficiency; however, the cause is often unknown. In azoospermia caused by hypogonadotropic hypogonadism, gonadotropin replacement therapy can be expected to produce sperm in the ejaculate. In some cases, upfront varicocelectomy for nonobstructive azoospermia with varicocele may result in the appearance of ejaculated spermatozoa; however, the appropriate indication should be selected. Each guideline recommends microdissection testicular sperm extraction for nonobstructive azoospermia in terms of successful sperm retrieval and avoidance of complications. Sperm retrieval rates generally ranged from 20% to 70% but vary depending on the causative disease. Various attempts have been made to predict sperm retrieval and improve sperm retrieval rates; however, the evidence is insufficient. Further evidence accumulation is needed for salvage treatment in cases of failed sperm retrieval. In Japan, there is inadequate provision on the right to know the origin of children born from artificial insemination of donated sperm and the rights of sperm donors, as well as information on unrelated family members, and the development of these systems is challenging. In the future, it is hoped that the pathogenesis of nonobstructive azoospermia with an unknown cause will be elucidated and that technology for omics technologies, human spermatogenesis using pluripotent cells, and organ culture methods will be developed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

57. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Author

Kawahara, Takashi, primary, Hasizume, Akihito, additional, Uemura, Koichi, additional, Yamaguchi, Katsuya, additional, Ito, Hiroki, additional, Takeshima, Teppei, additional, Hasumi, Hisashi, additional, Teranishi, Jun-ichi, additional, Ousaka, Kimito, additional, Makiyama, Kazuhide, additional, and Uemura, Hiroji, additional

Published
2023
Full Text
View/download PDF

64. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases

Author

Uemura, Hirotsugu, Uemura, Hiroji, Nagamori, Satsohi, Wakumoto, Yoshiaki, Kimura, Go, Kikukawa, Hiroaki, Yokomizo, Akira, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Akagawa, Takashi, and Matsubara, Nobuaki

Published
2019
Full Text
View/download PDF

65. Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases

Author

Takahashi, Shunji, Kinuya, Seigo, Nonomura, Norio, Shinohara, Nobuo, Suzuki, Kazuhiro, Suzuki, Hiroyoshi, Nakamura, Katsumasa, Satoh, Takefumi, Tateishi, Ukihide, Yoneda, Toshiyuki, Horikoshi, Hiroyuki, Igawa, Tsukasa, Kamai, Takao, Koizumi, Mitsuru, Kosaka, Takeo, Matsubara, Nobuaki, Miyake, Hideaki, Mizokami, Atsushi, Mizowaki, Takashi, Nakamura, Naoki, Nozawa, Masahiro, Takahashi, Takeo, Uemura, Hiroji, Uemura, Motohide, Yokomizo, Akira, Yoshimura, Mana, and Kakehi, Yoshiyuki

Published
2018
Full Text
View/download PDF

69. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Author

Matsubara, Nobuaki, Yamada, Yoko, Tabata, Ken-ichi, Satoh, Takefumi, Kamiya, Naoto, Suzuki, Hiroyoshi, Kawahara, Takashi, Uemura, Hiroji, Yano, Akihiro, Kawakami, Satoru, Otsuka, Masafumi, and Fukasawa, Satoshi

Published
2017
Full Text
View/download PDF

74. Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.

Author

Chung, Byung, Huang, Jian, Uemura, Hiroji, Choi, Young, Ye, Zhang-Qun, Suzuki, Hiroyoshi, Kang, Taek, He, Da-Lin, Joung, Jae, Brookman-May, Sabine, McCarthy, Sharon, Bhaumik, Amitabha, Singh, Anildeep, Mundle, Suneel, Chowdhury, Simon, Agarwal, Neeraj, Ye, Ding-Wei, Chi, Kim, and Uemura, Hirotsugu

Abstract

The final analysis of the phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial showed improvement in overall survival (OS) and other efficacy endpoints with apalutamide plus androgen deprivation therapy (ADT) versus ADT alone in patients with metastatic castration-sensitive prostate cancer (mCSPC). As ethnicity and regional differences may affect treatment outcomes in advanced prostate cancer, a post hoc final analysis was conducted to assess the efficacy and safety of apalutamide in the Asian subpopulation. Event-driven endpoints were OS, and time from randomization to initiation of castration resistance, prostate-specific antigen (PSA) progression, and second progression-free survival (PFS2) on first subsequent therapy or death. Efficacy endpoints were assessed using the Kaplan–Meier method and Cox proportional-hazards models without formal statistical testing and adjustment for multiplicity. Participating Asian patients received once-daily apalutamide 240 mg (n = 111) or placebo (n = 110) plus ADT. After a median follow-up of 42.5 months and despite crossover of 47 placebo recipients to open-label apalutamide, apalutamide reduced the risk of death by 32% (hazard ratio [HR]: 0.68; 95% confidence interval [CI]: 0.42–1.13), risk of castration resistance by 69% (HR: 0.31; 95% CI: 0.21–0.46), PSA progression by 79% (HR: 0.21; 95% CI: 0.13–0.35) and PFS2 by 24% (HR: 0.76; 95% CI: 0.44–1.29) relative to placebo. The outcomes were comparable between subgroups with low- and high-volume disease at baseline. No new safety issues were identified. Apalutamide provides valuable clinical benefits to Asian patients with mCSPC, with an efficacy and safety profile consistent with that in the overall patient population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

76. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma

Author

Nakaigawa, Noboru, Kondo, Keiichi, Kaneta, Tomohiro, Tateishi, Ukihide, Minamimoto, Ryogo, Namura, Kazuhiro, Ueno, Daiki, Kobayashi, Kazuki, Kishida, Takeshi, Ikeda, Ichiro, Hasumi, Hisashi, Makiyama, Kazuhide, Hayashi, Narihiko, Osaka, Kimito, Muraoka, Kentaro, Izumi, Koji, Kawahara, Takashi, Teranishi, Jun-ichi, Miyoshi, Yasuhide, Yumura, Yasushi, Uemura, Hiroji, Inoue, Tomio, and Yao, Masahiro

Published
2018
Full Text
View/download PDF

77. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Author

Matsubara, Nobuaki, Nagamori, Satsohi, Wakumoto, Yoshiaki, Uemura, Hirotsugu, Kimura, Go, Yokomizo, Akira, Kikukawa, Hiroaki, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Tsutsui, Hirokazu, and Uemura, Hiroji

Published
2018
Full Text
View/download PDF

79. Additional file 2 of Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

Author

Kawahara, Takashi, Saigusa, Yusuke, Yoneyama, Shuko, Kato, Masashi, Kojima, Ippei, Yamada, Hiroshi, Kamihira, Osamu, Tabata, Kenichi, Tsumura, Hideyasu, Iwamura, Masatsugu, Makiyama, Kazuhide, Uemura, Hiroji, and Miyoshi, Yasuhide

Abstract

Additional file 2: Supplementary Fig. 2. Kaplan–Meier curve of overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone first or enzalutamide first.

Published
2023
Full Text
View/download PDF

80. Additional file 1 of Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

Author

Kawahara, Takashi, Saigusa, Yusuke, Yoneyama, Shuko, Kato, Masashi, Kojima, Ippei, Yamada, Hiroshi, Kamihira, Osamu, Tabata, Kenichi, Tsumura, Hideyasu, Iwamura, Masatsugu, Makiyama, Kazuhide, Uemura, Hiroji, and Miyoshi, Yasuhide

Abstract

Additional file 1: Supplementary Fig. 1. Kaplan–Meier curve of overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone and/or enzalutamide.

Published
2023
Full Text
View/download PDF

83. Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab

Author

Tabei, Tadashi, Nakaigawa, Noboru, Kaneta, Tomohiro, Ikeda, Ichiro, Kondo, Keiichi, Makiyama, Kazuhide, Hasumi, Hisashi, Hayashi, Narihiko, Kawahara, Takashi, Izumi, Koji, Osaka, Kimito, Muraoka, Kentaro, Teranishi, Jun-ichi, Miyoshi, Yasuhide, Yumura, Yasushi, Uemura, Hiroji, Kobayashi, Kazuki, Inoue, Tomio, and Yao, Masahiro

Published
2019
Full Text
View/download PDF

84. Lower urinary tract symptoms are elevated with depression in Japanese women.

Author

Ninomiya, Sahoko, Kawahara, Takashi, Tsutsumi, Sohgo, Ito, Hiroki, Makiyama, Kazuhide, and Uemura, Hiroji

Subjects
DEPRESSION in women, JAPANESE women, URINARY organs, URINARY urge incontinence, MENTAL depression
Abstract

Objectives: Depression might worsen lower urinary tract symptoms (LUTS), but the correlation is still disputed. This study examined the influence of depression on LUTS in Japanese women. Methods: This study used a web‐based questionnaire to evaluate the mental status of depression and LUTS. The mental status of depression was evaluated using the Quick Inventory of Depressive Symptomatology‐Japanese version (QIDS‐J), and LUTS was assessed based on the Overactive Bladder Symptom Score (OABSS) and responses to the International Consultation on Incontinence Questionnaire‐Short Form. Results: A total of 4151 of 5400 (76.9%) women responded to the questionnaire. The mean age was 48.3 ± 13.8 years. The OABSS gradually increased with the QIDS‐J score. The incidence of overactive bladder (OAB) and urgency urinary incontinence (UUI) also increased along with the QIDS‐J score. In the younger age group (20–39 years old), the risks of OAB and UUI were higher than in the elderly group (7.42 for OAB and 7.44 for UUI). Conclusions: This study revealed that worsening of LUTS was correlated with depression. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

85. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study

Author

Uemura, Hiroji, primary, Oya, Mototsugu, additional, Kamoto, Toshiyuki, additional, Sugimoto, Mikio, additional, Shinozaki, Kenta, additional, Morita, Kiyomi, additional, Koto, Ryo, additional, Takahashi, Mai, additional, Nii, Masahiro, additional, Shin, Eisei, additional, and Nonomura, Norio, additional

Published
2022
Full Text
View/download PDF

87. The development and validation of a nomogram and calculator for survival among men treated with abiraterone acetate and/or enzalutamide for metastatic castration-resistant prostate cancer

Author

Kawahara, Takashi, primary, Saigusa, Yusuke, additional, Yoneyama, Shuko, additional, Kato, Masashi, additional, Kojima, Ippei, additional, Yamada, Hiroshi, additional, Kamihira, Osamu, additional, Tabata, Kenichi, additional, Tsumura, Hideyasu, additional, Iwamura, Masatsugu, additional, Makiyama, Kazuhide, additional, uemura, Hiroji, additional, and Miyoshi, Yasuhide, additional

Published
2022
Full Text
View/download PDF

88. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Author

Pollock, YaoYao, primary, Smith, Matthew R., additional, Saad, Fred, additional, Chowdhury, Simon, additional, Oudard, Stéphane, additional, Hadaschik, Boris, additional, Olmos, David, additional, Lee, Ji Youl, additional, Uemura, Hiroji, additional, Bhaumik, Amitabha, additional, Londhe, Anil, additional, Rooney, Brendan, additional, Brookman-May, Sabine D., additional, De Porre, Peter, additional, Mundle, Suneel D., additional, and Small, Eric J., additional

Published
2022
Full Text
View/download PDF

90. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival

Author

Ito, Hiroki, Kondo, Keiichi, Kawahara, Takashi, Kaneta, Tomohiro, Tateishi, Ukihide, Ueno, Daiki, Namura, Kazuhiro, Kobayashi, Kazuki, Miyoshi, Yasuhide, Yumura, Yasushi, Makiyama, Kazuhide, Hayashi, Narihiko, Hasumi, Hisashi, Osaka, Kimito, Yokomizo, Yumiko, Teranishi, Jun-ichi, Hattori, Yusuke, Inoue, Tomio, Uemura, Hiroji, Yao, Masahiro, and Nakaigawa, Noboru

Published
2017
Full Text
View/download PDF

91. Treatment strategies and outcomes in a long‐term registry study of patients with high‐risk metastatic hormone‐naïve prostate cancer in Japan: An interim analysis of the J‐ROCK study

Author

Uemura, Hirotsugu, primary, Matsumoto, Rikiya, additional, Mizokami, Atsushi, additional, Miyake, Hideaki, additional, Uemura, Hiroji, additional, Matsuyama, Hideyasu, additional, Nakamura, Kazuyoshi, additional, Saito, Kazutaka, additional, Kawakita, Mutsushi, additional, Takeshita, Hideki, additional, Koroki, Yosuke, additional, Ono, Shintaro, additional, Murota, Maiko, additional, Ito, Miku, additional, Kamoto, Toshiyuki, additional, and Fujimoto, Kiyohide, additional

Published
2022
Full Text
View/download PDF

94. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Turco, Fabio, primary, Armstrong, Andrew, additional, Attard, Gerhardt, additional, Beer, Tomasz M., additional, Beltran, Himisha, additional, Bjartell, Anders, additional, Bossi, Alberto, additional, Briganti, Alberto, additional, Bristow, Rob G., additional, Bulbul, Muhammad, additional, Caffo, Orazio, additional, Chi, Kim N., additional, Clarke, Caroline, additional, Clarke, Noel, additional, Davis, Ian D., additional, de Bono, Johann, additional, Duran, Ignacio, additional, Eeles, Ros, additional, Efstathiou, Eleni, additional, Efstathiou, Jason, additional, Evans, Christopher P., additional, Fanti, Stefano, additional, Feng, Felix Y., additional, Fizazi, Karim, additional, Frydenberg, Mark, additional, George, Dan, additional, Gleave, Martin, additional, Halabi, Susan, additional, Heinrich, Daniel, additional, Higano, Celestia, additional, Hofman, Michael S., additional, Hussain, Maha, additional, James, Nicholas, additional, Jones, Rob, additional, Kanesvaran, Ravindran, additional, Khauli, Raja B., additional, Klotz, Laurence, additional, Leibowitz, Raya, additional, Logothetis, Christopher, additional, Maluf, Fernando, additional, Millman, Robin, additional, Morgans, Alicia K., additional, Morris, Michael J., additional, Mottet, Nicolas, additional, Mrabti, Hind, additional, Murphy, Declan G., additional, Murthy, Vedang, additional, Oh, William K., additional, Ekeke Onyeanunam, Ngozi, additional, Ost, Piet, additional, O'Sullivan, Joe M., additional, Padhani, Anwar R., additional, Parker, Christopher, additional, Poon, Darren M.C., additional, Pritchard, Colin C., additional, Rabah, Danny M., additional, Rathkopf, Dana, additional, Reiter, Robert E., additional, Rubin, Mark, additional, Ryan, Charles J., additional, Saad, Fred, additional, Pablo Sade, Juan, additional, Sartor, Oliver, additional, Scher, Howard I., additional, Shore, Neal, additional, Skoneczna, Iwona, additional, Small, Eric, additional, Smith, Matthew, additional, Soule, Howard, additional, Spratt, Daniel, additional, Sternberg, Cora N., additional, Suzuki, Hiroyoshi, additional, Sweeney, Christopher, additional, Sydes, Matthew, additional, Taplin, Mary-Ellen, additional, Tilki, Derya, additional, Tombal, Bertrand, additional, Türkeri, Levent, additional, Uemura, Hiroji, additional, Uemura, Hirotsugu, additional, van Oort, Inge, additional, Yamoah, Kosj, additional, Ye, Dingwei, additional, Zapatero, Almudena, additional, Gillessen, Silke, additional, and Omlin, Aurelius, additional

Published
2022
Full Text
View/download PDF

96. Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.

Author

Thiery-Vuillemin, Antoine, primary, Saad, Fred, additional, Armstrong, Andrew J., additional, Oya, Mototsugu, additional, Vianna, Karina Costa Maia, additional, Özgüroğlu, Mustafa, additional, Gedye, Craig, additional, Buchschacher, Gary L, additional, Lee, Ji Youl, additional, Emmenegger, Urban, additional, Navratil, Jiri, additional, Virizuela, Juan Antonio, additional, Salazar, Anibal, additional, Maillet, Denis, additional, Uemura, Hiroji, additional, Kim, Jeri, additional, Lukacs, Edit, additional, Barker, Laura, additional, Degboe, Arnold N, additional, and Clarke, Noel W., additional

Published
2022
Full Text
View/download PDF

98. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study.

Author

Uemura, Hiroji, Oya, Mototsugu, Kamoto, Toshiyuki, Sugimoto, Mikio, Shinozaki, Kenta, Morita, Kiyomi, Koto, Ryo, Takahashi, Mai, Nii, Masahiro, Shin, Eisei, and Nonomura, Norio

Subjects
*CASTRATION-resistant prostate cancer, *JAPANESE people, *GENETIC mutation, *PROSTATE-specific antigen
Abstract

Background: Metastatic castration‐resistant prostate cancer (mCRPC) is a genetically heterogeneous disease with a poor prognosis. The prevalence of mutations in homologous recombination repair (HRR) pathway genes, including BRCA1/2, as well as treatment patterns and clinical outcomes, are not well characterized among Japanese men with mCRPC. Methods: This multicenter, noninterventional cohort study enrolled Japanese men with mCRPC from 24 institutions between 2014 and 2018. Mutations in the 15 HRR‐related genes were assessed using archival primary or metastatic tumor samples. Patterns of sequential therapies for mCRPC were investigated. Patients were followed up for survival evaluation including prostate‐specific antigen progression‐free survival (PSA‐PFS) and overall survival (OS). Results: Of the 143 patients analyzed, HRR‐related mutations were detected in 51 patients (35.7%). The most frequently mutated genes were CDK12 (N = 19, 13.3%), followed by BRCA2 (N = 18, 12.6%), ATM (N = 8, 5.6%), and CHEK2 (N = 3, 2.1%). The most common type of first‐line therapy for mCRPC was next‐generation hormonal agents (NHA, 44.4%), followed by first‐generation antiandrogens (FGA, 30.3%), and taxanes (22.5%). Commonly prescribed first−/second‐line sequential regimens included FGA/NHA (17.6%), NHA/NHA (15.5%), and NHA/taxanes (14.1%). The median PSA‐PFS and OS for the entire cohort were 5.6 and 26.1 months, respectively. Patients carrying BRCA1/2 mutations had numerically shorter PSA‐PFS (median 3.3 vs. 5.9 months) and OS (median 20.7 vs. 27.3 months) than those without mutations. Conclusions: In conclusion, approximately one‐third of Japanese patients with mCRPC carried mutations in HRR‐related genes in this study. The real‐world outcomes of mCRPC are poor with conventional therapy, warranting an expansion of treatment options based on genetic abnormalities of the disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results